Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Planchard

Showing results (71-80 of 243) with videos related to

Pageof 25
Sort By:
Cancers|January 11, 2022
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort ExperienceTina Lamy, Bastien Cabarrou, David Planchard, et al.
Investigational New Drugs|November 14, 2016
Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitorsPierre Loulergue, Mansouria Merad, Romain Coriat, et al.
JTO Clinical and Research Reports|May 2, 2022
Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case ReportMariona Riudavets, Benjamin Wyplosz, Maria Rosa Ghigna, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic valueFrancesco Facchinetti, Maria Virginia Bluthgen, Gabrielle Tergemina-Clain, et al.
Cancer Treatment Reviews|January 16, 2022
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)Fabrizio Tabbò, Chiara Pisano, Julien Mazieres, et al.
Virchows Archiv : an International Journal of Pathology|December 13, 2024
Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasmsChristina Kanaan, Mohamed-Amine Bani, Michel Ducreux, et al.
Lung Cancer (Amsterdam, Netherlands)|December 22, 2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancerBenjamin Besse, David Planchard, Anne-Sophie Veillard, et al.
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
JAMA Oncology|June 12, 2020
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung CancerBaptiste Kas, Hugues Talbot, Roberto Ferrara, et al.
Expert Review of Molecular Diagnostics|November 14, 2015
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancerKirsty Ross, Emma Pailler, Vincent Faugeroux, et al.
Pageof 25

Showing results (71-80 of 243) with videos related to

Sort By:
Pageof 25
Cancers|January 11, 2022
Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort ExperienceTina Lamy, Bastien Cabarrou, David Planchard, et al.
Investigational New Drugs|November 14, 2016
Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitorsPierre Loulergue, Mansouria Merad, Romain Coriat, et al.
JTO Clinical and Research Reports|May 2, 2022
Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case ReportMariona Riudavets, Benjamin Wyplosz, Maria Rosa Ghigna, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic valueFrancesco Facchinetti, Maria Virginia Bluthgen, Gabrielle Tergemina-Clain, et al.
Cancer Treatment Reviews|January 16, 2022
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC)Fabrizio Tabbò, Chiara Pisano, Julien Mazieres, et al.
Virchows Archiv : an International Journal of Pathology|December 13, 2024
Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasmsChristina Kanaan, Mohamed-Amine Bani, Michel Ducreux, et al.
Lung Cancer (Amsterdam, Netherlands)|December 22, 2011
Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancerBenjamin Besse, David Planchard, Anne-Sophie Veillard, et al.
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
JAMA Oncology|June 12, 2020
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung CancerBaptiste Kas, Hugues Talbot, Roberto Ferrara, et al.
Expert Review of Molecular Diagnostics|November 14, 2015
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancerKirsty Ross, Emma Pailler, Vincent Faugeroux, et al.
Pageof 25